Xiao, F. .; Xiao, W. .; Li, X.; Li, R. .; Zhao, K. . Cost-Effectiveness Analysis of Trastuzumab Deruxtecan As Second-Line Treatment for HER2- Positive Advanced Breast Cancer. Health Decision 2024, 2.